How Rare Cannabinoids are Disrupting the Pharmaceutical Industry-DrugTopics

How Rare Cannabinoids are Disrupting the Pharmaceutical Industry

CEO and Founder of BIOMEDICAN, Maxim Mikheev, explained biosynthesis, usage of rare cannabinoids, and their impact on pharmaceuticals in the recent publication “How Rare Cannabinoids Are Disrupting the Pharmaceutical Industry.”

In addition to the most well-known cannabinoids, such as cannabidiol (CBD) and tetrahydrocannabinol (THC), the latest research found various rare cannabinoids like cannabigerol (CBG), cannabinol (CBN), and tetrahydrocannabivarin (THCV). These rare cannabinoids are inexpensive and more potent without psychoactive effects. Maxim expects that rare cannabinoids will transform the pharmaceutical industry. According to market analysts, cannabinoid-based pharmaceuticals will reach $50 billion by 2029.

The Endocannabinoid system (ECS) of our body regulates various functions and processes such as sleep, appetite, mood, memory, production, and fertility. Endocannabinoids bind the receptor and trigger a signaling cascade that performs the required action. Enzymes of ECS destroy these cannabinoids after the completion of targeted action. Rare cannabinoids play their role in ECS, just like endocannabinoids.

Cannabinoids have the potential to disrupt the pharmaceutical industry. Over 50 preclinical and clinical studies have suggested a potential value for CBD in some neuropsychiatric disorders, including epilepsy, anxiety, and schizophrenia. Biomedican developed a patented method of cannabinoids’ biosynthesis, which is 75% to 90% cheaper, contamination-free, and environment friendly. Biosynthesis of rare cannabinoids will give pharmaceutical companies more incentive to use them as buyers receive insurance reimbursement.

Rare cannabinoids like CBG/CBGA, CBN/CBNA, THCV/THCVA, and THCA will have a vast impact on the medical industry. Cannabinoid-based pharmaceuticals are expected to overtake the market due to the numerous medical benefits and cost-effectiveness of the rare cannabinoids. THCV/THCVA has been observed to help diabetes, pain and swelling, anxiety, and tremors from Parkinson’s disease and amyotrophic lateral sclerosis. Moreover, CBN/CBNA is well-known to relieve insomnia, pain, and anxiety. CBN/CBNA works as an antibacterial and anti-convulsive agent. CBN can increase appetite without psychoactive effects.

Researchers at Biomedican have designed a way to yield these more effective but less costly rare cannabinoids. To learn more about rare cannabinoids, visit our website.

Saba IqbalAuthor posts

Dr. Saba Iqbal is a contributing writer for BioMedican. She's a clinical pharmacist turned writer. Dr. Saba's education includes a doctoral degree in pharmacy (Pharm D) from the University of Sargodha, Pakistan. In search of a career that would take advantage of her medical and pharmaceutical skills, Dr. Saba found medical writing – a career path a few medical students consider. In her journey "from a medical bench to pen," she has worked with several startups for many years managing content on biotech products, pharmaceuticals, drugs, devices, and techniques. While keeping up with the latest trends in medical writing, she aims to use her writing skills to clearly communicate complex scientific, medical, and health information to the potential investor and general audience.

Comments are disabled.